JP2008505190A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008505190A5 JP2008505190A5 JP2007527363A JP2007527363A JP2008505190A5 JP 2008505190 A5 JP2008505190 A5 JP 2008505190A5 JP 2007527363 A JP2007527363 A JP 2007527363A JP 2007527363 A JP2007527363 A JP 2007527363A JP 2008505190 A5 JP2008505190 A5 JP 2008505190A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- foreign compound
- bone
- administration
- lrp5
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 238
- 238000000034 method Methods 0.000 claims 132
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 claims 119
- 101001039199 Homo sapiens Low-density lipoprotein receptor-related protein 6 Proteins 0.000 claims 119
- 108090000623 proteins and genes Proteins 0.000 claims 93
- 102000004169 proteins and genes Human genes 0.000 claims 92
- 150000002632 lipids Chemical class 0.000 claims 88
- 239000012634 fragment Substances 0.000 claims 74
- 210000004027 cell Anatomy 0.000 claims 54
- 230000027455 binding Effects 0.000 claims 52
- 239000000203 mixture Substances 0.000 claims 51
- 108090000765 processed proteins & peptides Proteins 0.000 claims 44
- 230000001225 therapeutic effect Effects 0.000 claims 44
- 241000124008 Mammalia Species 0.000 claims 38
- 102000013814 Wnt Human genes 0.000 claims 36
- 108050003627 Wnt Proteins 0.000 claims 36
- 230000010072 bone remodeling Effects 0.000 claims 36
- 230000011164 ossification Effects 0.000 claims 35
- 210000000988 bone and bone Anatomy 0.000 claims 34
- 206010028980 Neoplasm Diseases 0.000 claims 30
- 230000005856 abnormality Effects 0.000 claims 30
- 208000020084 Bone disease Diseases 0.000 claims 29
- 230000003993 interaction Effects 0.000 claims 29
- 206010061363 Skeletal injury Diseases 0.000 claims 28
- 206010017076 Fracture Diseases 0.000 claims 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims 26
- 229930186217 Glycolipid Natural products 0.000 claims 22
- 102000003886 Glycoproteins Human genes 0.000 claims 22
- 108090000288 Glycoproteins Proteins 0.000 claims 22
- 239000005557 antagonist Substances 0.000 claims 22
- 125000004122 cyclic group Chemical group 0.000 claims 22
- 230000012010 growth Effects 0.000 claims 22
- 125000000623 heterocyclic group Chemical group 0.000 claims 22
- 102000039446 nucleic acids Human genes 0.000 claims 22
- 108020004707 nucleic acids Proteins 0.000 claims 22
- 150000007523 nucleic acids Chemical class 0.000 claims 22
- 229920001184 polypeptide Polymers 0.000 claims 22
- 150000003384 small molecules Chemical class 0.000 claims 22
- 230000004936 stimulating effect Effects 0.000 claims 22
- 235000000346 sugar Nutrition 0.000 claims 22
- 102000004895 Lipoproteins Human genes 0.000 claims 21
- 108090001030 Lipoproteins Proteins 0.000 claims 21
- 108020003175 receptors Proteins 0.000 claims 21
- 102000005962 receptors Human genes 0.000 claims 21
- 239000000126 substance Substances 0.000 claims 21
- 241001465754 Metazoa Species 0.000 claims 20
- 201000010099 disease Diseases 0.000 claims 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 19
- 230000001737 promoting effect Effects 0.000 claims 19
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 18
- 208000010392 Bone Fractures Diseases 0.000 claims 18
- 108010006519 Molecular Chaperones Proteins 0.000 claims 18
- 238000012216 screening Methods 0.000 claims 14
- 240000007113 Rumex obtusifolius Species 0.000 claims 13
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 claims 11
- 239000000556 agonist Substances 0.000 claims 11
- 238000000338 in vitro Methods 0.000 claims 11
- 239000003112 inhibitor Substances 0.000 claims 11
- 239000004031 partial agonist Substances 0.000 claims 11
- 230000035755 proliferation Effects 0.000 claims 11
- 102100040704 Low-density lipoprotein receptor-related protein 6 Human genes 0.000 claims 9
- 101150021503 Mesd gene Proteins 0.000 claims 9
- 238000007918 intramuscular administration Methods 0.000 claims 8
- 238000007912 intraperitoneal administration Methods 0.000 claims 8
- 238000001990 intravenous administration Methods 0.000 claims 8
- 238000007911 parenteral administration Methods 0.000 claims 8
- 238000007920 subcutaneous administration Methods 0.000 claims 8
- 238000011200 topical administration Methods 0.000 claims 8
- 208000015181 infectious disease Diseases 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 108010001831 LDL receptors Proteins 0.000 claims 5
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 5
- 208000036142 Viral infection Diseases 0.000 claims 5
- 230000001105 regulatory effect Effects 0.000 claims 5
- 238000007634 remodeling Methods 0.000 claims 5
- 230000010076 replication Effects 0.000 claims 5
- 230000009385 viral infection Effects 0.000 claims 5
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 claims 4
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 claims 4
- 102100030091 Dickkopf-related protein 2 Human genes 0.000 claims 4
- 101710099523 Dickkopf-related protein 2 Proteins 0.000 claims 4
- 102100037985 Dickkopf-related protein 3 Human genes 0.000 claims 4
- 101710099550 Dickkopf-related protein 3 Proteins 0.000 claims 4
- 102100037986 Dickkopf-related protein 4 Human genes 0.000 claims 4
- 101710099554 Dickkopf-related protein 4 Proteins 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- 230000003822 cell turnover Effects 0.000 claims 4
- 230000004069 differentiation Effects 0.000 claims 4
- 230000004957 immunoregulator effect Effects 0.000 claims 4
- 210000000581 natural killer T-cell Anatomy 0.000 claims 4
- 150000008163 sugars Chemical class 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 3
- 230000024245 cell differentiation Effects 0.000 claims 3
- 230000004663 cell proliferation Effects 0.000 claims 3
- 239000008298 dragée Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000000499 gel Substances 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 239000006187 pill Substances 0.000 claims 3
- 239000002002 slurry Substances 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- 239000006188 syrup Substances 0.000 claims 3
- 235000020357 syrup Nutrition 0.000 claims 3
- 239000003826 tablet Substances 0.000 claims 3
- 230000007306 turnover Effects 0.000 claims 3
- 102000051172 Axin Human genes 0.000 claims 2
- 108700012045 Axin Proteins 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 101100210337 Drosophila melanogaster wntD gene Proteins 0.000 claims 2
- 102000005698 Frizzled receptors Human genes 0.000 claims 2
- 108010045438 Frizzled receptors Proteins 0.000 claims 2
- 206010017533 Fungal infection Diseases 0.000 claims 2
- 108091007911 GSKs Proteins 0.000 claims 2
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 208000037262 Hepatitis delta Diseases 0.000 claims 2
- 208000031888 Mycoses Diseases 0.000 claims 2
- 208000030852 Parasitic disease Diseases 0.000 claims 2
- 102000000479 TCF Transcription Factors Human genes 0.000 claims 2
- 108010016283 TCF Transcription Factors Proteins 0.000 claims 2
- 101150109862 WNT-5A gene Proteins 0.000 claims 2
- 101150019524 WNT2 gene Proteins 0.000 claims 2
- 102000052547 Wnt-1 Human genes 0.000 claims 2
- 108700020987 Wnt-1 Proteins 0.000 claims 2
- 102000052556 Wnt-2 Human genes 0.000 claims 2
- 108700020986 Wnt-2 Proteins 0.000 claims 2
- 102000043366 Wnt-5a Human genes 0.000 claims 2
- 108700020483 Wnt-5a Proteins 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 230000008485 antagonism Effects 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 210000002449 bone cell Anatomy 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 208000029570 hepatitis D virus infection Diseases 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 230000001900 immune effect Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 2
- 210000000963 osteoblast Anatomy 0.000 claims 2
- 230000003094 perturbing effect Effects 0.000 claims 2
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- 210000002536 stromal cell Anatomy 0.000 claims 2
- PIVQQUNOTICCSA-UHFFFAOYSA-N ANTU Chemical compound C1=CC=C2C(NC(=S)N)=CC=CC2=C1 PIVQQUNOTICCSA-UHFFFAOYSA-N 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 244000090689 Rumex alpinus Species 0.000 claims 1
- 230000010478 bone regeneration Effects 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/849,067 US8637506B2 (en) | 2003-09-22 | 2004-05-19 | Compositions and methods for bone formation and remodeling |
| PCT/US2005/017199 WO2005115354A2 (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008505190A JP2008505190A (ja) | 2008-02-21 |
| JP2008505190A5 true JP2008505190A5 (enExample) | 2008-07-03 |
Family
ID=35451375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007527363A Pending JP2008505190A (ja) | 2004-05-19 | 2005-05-18 | 骨の形成と再構築のための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8637506B2 (enExample) |
| EP (3) | EP3150255A1 (enExample) |
| JP (1) | JP2008505190A (enExample) |
| CN (1) | CN101316627A (enExample) |
| CA (6) | CA2567023C (enExample) |
| IL (1) | IL179241A (enExample) |
| WO (1) | WO2005115354A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6780609B1 (en) * | 1998-10-23 | 2004-08-24 | Genome Therapeutics Corporation | High bone mass gene of 1.1q13.3 |
| US6770461B1 (en) * | 1998-10-23 | 2004-08-03 | Genome Therapeutics Corporation | High bone mass gene of 11q13.3 |
| BR0209563A (pt) * | 2001-05-11 | 2004-12-07 | Genome Theraupeutics Corp | ácido nucleico, polipeptìdeo, vetor, célula, anticorpo, métodos de diagnosticar um fenótipo e um paciente como expressando um ácido nucleico e de identificar agentes que modulam a atividade de um ácido nucleico e de uma proteìna e lrp5, lrp6, ou hbm e compostos que modulam a interação de dkk com o caminho de sinalização wnt, composição para modular a massa óssea e/ou os nìveis de lipìdeo em um paciente, animal transgênico, embrião e modelo de animal, e, agente |
| US20040221326A1 (en) * | 2001-05-11 | 2004-11-04 | Philip Babij | Transgenic animal model of bone mass modulation |
| US20030219793A1 (en) * | 2002-10-04 | 2003-11-27 | Carulli John P. | High bone mass gene of 11q13.3 |
| US7485460B2 (en) * | 2003-05-21 | 2009-02-03 | Tulane University Health Sciences Center | Enhanced growth of adult stem cells with Dkk-1 |
| US8367822B2 (en) | 2003-09-22 | 2013-02-05 | Enzo Therapeutics, Inc. | Compositions and methods for bone formation and remodeling |
| US20100041599A1 (en) | 2006-11-14 | 2010-02-18 | Dakai Liu | Compositions and methods for bone formation, bone remodeling and toxin protection |
| US8637506B2 (en) * | 2003-09-22 | 2014-01-28 | Enzo Biochem, Inc. | Compositions and methods for bone formation and remodeling |
| US8461155B2 (en) * | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| US20120178697A9 (en) * | 2003-09-22 | 2012-07-12 | Jie Zheng | Compositions and methods for the inhibition of dishevelled proteins |
| US9046537B2 (en) | 2003-09-22 | 2015-06-02 | Enzo Biochem, Inc. | Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain |
| US8343922B2 (en) * | 2004-05-19 | 2013-01-01 | Enzo Biochem, Inc. | Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells |
| US9052324B2 (en) | 2004-05-19 | 2015-06-09 | Enzo Biochem, Inc. | Compounds and assays for controlling Wnt activity |
| JP2010526090A (ja) * | 2007-04-30 | 2010-07-29 | ワシントン・ユニバーシティ | 癌の治療のための方法および組成物 |
| WO2008144659A2 (en) * | 2007-05-18 | 2008-11-27 | Board Of Regents, The University Of Texas System | Dickkopf-1 (dkk1) as a universal tumor vaccine for immunotherapy of cancers |
| ES2560532T3 (es) * | 2007-11-02 | 2016-02-19 | Novartis Ag | Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (LRP6) |
| US8715941B2 (en) | 2007-11-16 | 2014-05-06 | Arca Biopharma, Inc. | Antibodies to LRP6 |
| US8716243B2 (en) * | 2008-05-28 | 2014-05-06 | St. Jude Childen's Research Hospital | Methods of effecting Wnt signaling through Dkk structural analysis |
| WO2010108001A2 (en) * | 2009-03-18 | 2010-09-23 | The Brigham And Women's Hospital, Inc. | Agents and methods for tissue repair and regeneration |
| PE20120475A1 (es) | 2009-05-12 | 2012-05-05 | Pfizer | Anticuerpos especificos para dkk-1 |
| US9290573B2 (en) | 2010-05-06 | 2016-03-22 | Novartis Ag | Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies |
| ES2659406T3 (es) | 2010-05-06 | 2018-03-15 | Novartis Ag | Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6) |
| US9493541B2 (en) | 2010-06-07 | 2016-11-15 | Joshua Rabbani | Antibodies specific for sulfated sclerostin |
| US9617323B2 (en) | 2010-06-07 | 2017-04-11 | Joshua Rabbani | Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor |
| US9403882B2 (en) | 2010-06-07 | 2016-08-02 | Joshua Rabbani | Sulfation of Wnt pathway proteins |
| US11167011B2 (en) | 2010-06-07 | 2021-11-09 | Enzo Biochem, Inc. | Methods for treating bone loss using sclerostin peptides |
| EP2663576B1 (en) * | 2011-01-11 | 2017-11-01 | Fate Therapeutics, Inc. | Novel wnt compositions and therapeutic uses of such compositions |
| KR101303941B1 (ko) | 2011-03-31 | 2013-09-05 | 연세대학교 산학협력단 | 피마자 추출물을 유효성분으로 함유하는 골 질환 예방 및 치료용 조성물 |
| MX2014005411A (es) | 2011-11-04 | 2015-02-12 | Novartis Ag | Construcciones prolongadas de la vida media de la proteina relacionada con lipoproteina de baja densidad 6 (lrp6). |
| CN103966229A (zh) * | 2014-05-09 | 2014-08-06 | 中山大学 | bbeAMP基因、其编码的蛋白质、以bbeAMP为目的基因生产的融合蛋白及其应用 |
| JP6796059B2 (ja) | 2014-09-12 | 2020-12-02 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｗｎｔシグナリングアゴニスト分子 |
| CN106367517A (zh) * | 2016-09-28 | 2017-02-01 | 湖北工业大学 | 一种低密度脂蛋白受体相关蛋白5基因突变检测的试剂及应用 |
| CA3085596A1 (en) | 2017-12-19 | 2019-06-27 | Surrozen, Inc. | Anti-frizzled antibodies and methods of use |
| US11773171B2 (en) | 2017-12-19 | 2023-10-03 | Surrozen Operating, Inc. | WNT surrogate molecules and uses thereof |
| US11746150B2 (en) | 2017-12-19 | 2023-09-05 | Surrozen Operating, Inc. | Anti-LRP5/6 antibodies and methods of use |
| CN111632147A (zh) * | 2020-06-07 | 2020-09-08 | 重庆医科大学 | 骨细胞Wnt激活剂在制备骨折加速愈合、防治骨不连及不运动或失重骨丢失药物中的应用 |
| CN115309402B (zh) * | 2022-07-13 | 2023-10-24 | 国网江苏省电力有限公司信息通信分公司 | 一种可量化差异的异构执行程序集合构成方法及装置 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS562623A (en) * | 1979-06-21 | 1981-01-12 | Matsushita Electric Industrial Co Ltd | Electrode |
| DE69420649T2 (de) * | 1993-08-19 | 2000-05-04 | Advanced Micro Devices, Inc. | Voll differentieller Operationsverstärker mit niedriger Versorgungsspannung |
| US7244577B2 (en) * | 1997-04-15 | 2007-07-17 | Merck & Co., Inc. | Method of screening for modulator of LRP5 activity |
| DE19747418C1 (de) * | 1997-10-27 | 1999-07-15 | Deutsches Krebsforsch | Inhibitor-Protein des wnt-Signalwegs |
| US20040009535A1 (en) * | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| WO2000052047A2 (en) * | 1999-03-05 | 2000-09-08 | Millennium Pharmaceuticals, Inc. | Human dickkopf-related protein and nucleic acid molecules and uses therefor |
| AU5623801A (en) * | 2000-03-29 | 2001-10-08 | Max Planck Gesellschaft | 3d structure of polypeptides containing a tpr-structure motif with chaperone-binding function, crystals thereof and compounds for inhibition of said peptides |
| US7713526B2 (en) * | 2001-05-01 | 2010-05-11 | The Regents Of The University Of California | Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
| US20040038860A1 (en) * | 2002-05-17 | 2004-02-26 | Allen Kristina M. | Reagents and methods for modulating dkk-mediated interactions |
| CA2446582A1 (en) | 2001-05-17 | 2002-11-21 | Genome Therapeutics Corporation | Reagents and methods for modulating dkk-mediated interactions |
| WO2003039534A1 (en) * | 2001-11-08 | 2003-05-15 | Merck & Co., Inc. | Compositions and methods for treating osteoporosis |
| AU2003276430A1 (en) | 2002-06-14 | 2003-12-31 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| US20050084494A1 (en) * | 2003-05-21 | 2005-04-21 | Darwin Prockop | Inhibitors of Dkk-1 |
| US8637506B2 (en) | 2003-09-22 | 2014-01-28 | Enzo Biochem, Inc. | Compositions and methods for bone formation and remodeling |
| US20120178697A9 (en) | 2003-09-22 | 2012-07-12 | Jie Zheng | Compositions and methods for the inhibition of dishevelled proteins |
| US9046537B2 (en) * | 2003-09-22 | 2015-06-02 | Enzo Biochem, Inc. | Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain |
| US8367822B2 (en) * | 2003-09-22 | 2013-02-05 | Enzo Therapeutics, Inc. | Compositions and methods for bone formation and remodeling |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| US8343922B2 (en) * | 2004-05-19 | 2013-01-01 | Enzo Biochem, Inc. | Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells |
| ES2414460T3 (es) * | 2004-08-04 | 2013-07-19 | Amgen Inc. | Anticuerpos para Dkk-1 |
| US7838252B2 (en) * | 2005-02-17 | 2010-11-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating a subject having an anthrax toxin mediated condition |
-
2004
- 2004-05-19 US US10/849,067 patent/US8637506B2/en not_active Expired - Lifetime
-
2005
- 2005-05-18 CN CNA2005800243835A patent/CN101316627A/zh active Pending
- 2005-05-18 WO PCT/US2005/017199 patent/WO2005115354A2/en not_active Ceased
- 2005-05-18 JP JP2007527363A patent/JP2008505190A/ja active Pending
- 2005-05-18 CA CA2567023A patent/CA2567023C/en not_active Expired - Lifetime
- 2005-05-18 EP EP16000780.3A patent/EP3150255A1/en not_active Withdrawn
- 2005-05-18 CA CA2771951A patent/CA2771951C/en not_active Expired - Lifetime
- 2005-05-18 CA CA2772033A patent/CA2772033C/en not_active Expired - Lifetime
- 2005-05-18 CA CA2771940A patent/CA2771940C/en not_active Expired - Lifetime
- 2005-05-18 CA CA2771941A patent/CA2771941C/en not_active Expired - Lifetime
- 2005-05-18 EP EP11184755.4A patent/EP2409732B1/en not_active Expired - Lifetime
- 2005-05-18 EP EP05751764A patent/EP1758562B1/en not_active Expired - Lifetime
- 2005-05-18 CA CA2772029A patent/CA2772029C/en not_active Expired - Lifetime
-
2006
- 2006-11-13 IL IL179241A patent/IL179241A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008505190A5 (enExample) | ||
| JP7549907B2 (ja) | 心不全の治療用組成物 | |
| CA2567023A1 (en) | Compositions and methods for bone formation and remodeling | |
| US12133882B2 (en) | Neuregulin based methods for treating heart failure | |
| US9089524B2 (en) | Neuregulin based methods for treating heart failure | |
| US20210347840A1 (en) | Compositions and methods for treating heart failure in diabetic patients | |
| EP3087998B1 (en) | Neuregulin based methods for treating heart failure | |
| JP2017125032A (ja) | 糖尿病患者における心不全の治療用組成物 | |
| HK1231890B (en) | Neuregulin for treating heart failure |